Get the Stockscreener App
15.98
2.86%
-0.47
After Hours:
15.98
Entrada Therapeutics Inc stock is traded at $15.98, with a volume of 158.29K.
It is down -2.86% in the last 24 hours and down -9.72% over the past month.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
See More
Previous Close:
$16.45
Open:
$16.3
24h Volume:
158.29K
Relative Volume:
1.09
Market Cap:
$594.45M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
-6.1938
EPS:
-2.58
Net Cash Flow:
$-18.50M
1W Performance:
+9.68%
1M Performance:
-9.72%
6M Performance:
+12.77%
1Y Performance:
+1.14%
1-Day Range:
$15.59
$16.66
1-Week Range:
$14.49
$17.38
52-Week Range:
$10.75
$18.17
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
Entrada Therapeutics (NASDAQ:TRDA) Trading 4.8% Higher - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Trading 4.8% Higher - Defense World
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - Markets Insider
Entrada Therapeutics appoints new President of R&D - Investing.com
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - GlobeNewswire
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - The Bakersfield Californian
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
30 Shares in Mettler-Toledo International Inc. (NYSE:MTD) Acquired by Itau Unibanco Holding S.A. - Defense World
STERIS plc (NYSE:STE) Shares Sold by XTX Topco Ltd - Defense World
Mettler-Toledo International's (NYSE:MTD) investors will be pleased with their decent 100% return over the last five years - Simply Wall St
Mutual of America Capital Management LLC Cuts Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Lavaca Capital LLC Acquires New Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Purchased by Epoch Investment Partners Inc. - Defense World
Seven Eight Capital LP Has $607,000 Stake in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Holdings Lowered by Ensign Peak Advisors Inc - Defense World
Entrada Therapeutics (NASDAQ:TRDA) Shares Up 6.7% - Defense World
GM Advisory Group LLC Takes $214,000 Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Acquired by Beddow Capital Management Inc. - Defense World
Dimensional Fund Advisors LP Cuts Stake in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Bought by Axxcess Wealth Management LLC - Defense World
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Up 6.7% - MarketBeat
Tredje AP fonden Trims Stock Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Stake Reduced by Meiji Yasuda Asset Management Co Ltd. - Defense World
XTX Topco Ltd Invests $2.49 Million in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Inspire Investing LLC Sells 357 Shares of Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Acquired by Meiji Yasuda Life Insurance Co - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Purchased by Dai ichi Life Insurance Company Ltd - Defense World
Federated Hermes Inc. Has $10.72 Million Holdings in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors - Business Wire
Quest Partners LLC Has $147,000 Stake in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Sold by Commonwealth Equity Services LLC - Defense World
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors - Yahoo Finance
(TRDA) Technical Data - Stock Traders Daily
Entrada Therapeutics CFO sells shares worth over $47,000 By Investing.com - Investing.com Australia
Entrada Therapeutics CFO sells shares worth over $47,000 - Investing.com India
Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden Sells 1,904 Shares - MarketBeat
Entrada Therapeutics CFO sells shares worth over $47,000 - Investing.com
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program - ForexTV.com
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program - Marketscreener.com
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program - GlobeNewswire Inc.
Entrada Therapeutics (NASDAQ:TRDA) Trading Down 11.2% - MarketBeat
Oppenheimer Reaffirms "Outperform" Rating for Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics’ (TRDA) “Outperform” Rating Reaffirmed at Oppenheimer - Defense World
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Down 3% - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates - MSN
Entrada Therapeutics exec sells over $440k in company stock - Investing.com India
Entrada Therapeutics exec sells over $440k in company stock - Investing.com
Entrada Therapeutics exec sells over $440k in company stock By Investing.com - Investing.com UK
California State Teachers Retirement System Lowers Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics (NASDAQ:TRDA) Sees Strong Trading Volume - MarketBeat
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):